Last updated: September 5, 2026
UNIVASC, the brand name for moexipril hydrochloride, is an antihypertensive angiotensin-converting enzyme inhibitor that reached the U.S. market in the mid-1990s. Its commercial trajectory followed the standard pattern for an older small-molecule cardiovascular drug: initial branded uptake, erosion after generic entry, declining promotional support, and eventual loss of meaningful market relevance.
UNIVASC is no longer a major branded pharmaceutical asset. Its commercial value is limited to historical sales, residual generic demand, and any remaining regulatory or intellectual-property rights in selected jurisdictions. Public sources do not disclose reliable product-level revenue for UNIVASC, so its financial trajectory is best assessed through approval history, therapeutic substitution, generic competition, and corporate portfolio changes.
What is UNIVASC and how does moexipril work?
UNIVASC contains moexipril hydrochloride, an orally administered ACE inhibitor used to treat hypertension. Moexipril is converted in vivo to moexiprilat, the pharmacologically active metabolite. The drug reduces angiotensin II formation, lowers aldosterone activity, and decreases blood pressure.
| Attribute |
UNIVASC |
| Active ingredient |
Moexipril hydrochloride |
| Active metabolite |
Moexiprilat |
| Drug class |
ACE inhibitor |
| Primary indication |
Hypertension |
| Dosage forms |
Oral tablets |
| Original U.S. sponsor |
Schwarz Pharma |
| U.S. regulatory pathway |
New Drug Application |
| Commercial status |
Mature or discontinued branded product |
| Current strategic value |
Limited branded value; primarily historical and generic |
The FDA labeling described UNIVASC as a treatment for hypertension, either alone or with other antihypertensive agents. The label included the standard ACE-inhibitor risks of angioedema, hypotension, renal impairment, hyperkalemia, and fetal toxicity. [1]
When did UNIVASC launch and lose exclusivity?
UNIVASC received U.S. FDA approval in the mid-1990s. The product entered a highly competitive ACE-inhibitor market that already included captopril, enalapril, lisinopril, quinapril, ramipril, benazepril, and fosinopril.
The commercial window for UNIVASC was constrained by three factors:
- ACE inhibitors were already a mature class when moexipril launched.
- Several competing products had stronger physician familiarity and broader formularies.
- Generic substitution became increasingly aggressive as patents and regulatory exclusivities expired across the class.
A precise UNIVASC patent-expiration date cannot be established from the public sources used for this assessment without relying on an authenticated historical Orange Book record or complete patent-family review. Product-level exclusivity, patent expiry, and generic-launch dates should not be inferred solely from the approval date.
UNIVASC exclusivity timeline
| Period |
Commercial event |
Market effect |
| Mid-1990s |
FDA approval and branded launch |
Entry into established ACE-inhibitor market |
| Late 1990s |
Expansion of generic ACE-inhibitor competition |
Reduced differentiation |
| Early 2000s |
Mature formulary and physician adoption patterns |
Pressure on branded share |
| Later commercial period |
Generic moexipril availability or declining brand support |
Loss of branded pricing power |
| Current period |
Limited branded relevance |
Generic or therapeutic substitution dominates |
UNIVASC did not develop the durable commercial franchise associated with larger cardiovascular brands such as Zestril, Prinivil, Vasotec, Altace, or Lotensin.
What patents protected UNIVASC?
UNIVASC was protected historically by compound, formulation, manufacturing, and potentially method-of-use rights associated with moexipril and its pharmaceutical compositions. The principal commercial protection would have been the right to sell moexipril tablets without approved generic competition during the enforceable life of relevant patents and regulatory exclusivities.
Public product labeling confirms the drug’s composition and indications but does not provide a complete patent map. A reliable patent analysis would require matching:
- The original moexipril compound patents
- U.S. Orange Book listings for the approved NDA
- Continuation and divisional applications
- Patent-term-adjustment records
- Any pediatric or regulatory exclusivity
- ANDA litigation and Paragraph IV notices
- Historical assignments involving Schwarz Pharma and successor companies
The absence of a current high-value branded market materially reduces the practical importance of residual UNIVASC patent rights. Any surviving rights would need to be evaluated by jurisdiction, claim scope, enforceability, and whether the claims cover the active ingredient, a specific tablet formulation, or a manufacturing process.
What formulations were protected by UNIVASC patents?
UNIVASC was marketed as an oral tablet. Formulation-related rights could have covered:
- Moexipril hydrochloride dosage forms
- Tablet excipient combinations
- Stability and dissolution characteristics
- Salt or polymorphic forms
- Processes for producing moexipril or moexiprilat intermediates
Formulation patents are generally less commercially durable than a valid composition-of-matter patent unless they prevent a practical generic design-around. For a mature ACE inhibitor, generic manufacturers could often compete through alternative excipients, manufacturing processes, or non-infringing tablet compositions.
How strong was the UNIVASC patent estate?
The UNIVASC patent estate was commercially moderate at launch but weak as a current investment asset.
Strengths
- Moexipril was protected as a prescription pharmaceutical during the early branded period.
- The product had an FDA-approved hypertension indication.
- Tablet formulations were commercially straightforward to manufacture.
- Regulatory approval provided a defined pathway for generic applicants.
Weaknesses
- The drug competed in a crowded ACE-inhibitor class.
- Clinical differentiation from established ACE inhibitors was limited.
- Antihypertensive prescribing became increasingly price-sensitive.
- Generic manufacturers could compete through conventional oral-solid-dose production.
- No major orphan, biologic, delivery-system, or specialty-pharmacy barrier protected the product.
- Brand value was not supported by a unique administration system or narrow specialist market.
The current patent position should be treated as low-value unless a surviving jurisdiction-specific patent has unusually broad claims or a manufacturing process that is difficult to design around.
What was the FDA regulatory status of UNIVASC?
UNIVASC was approved for hypertension through the FDA’s conventional small-molecule NDA process. It was not a biologic, did not create biosimilar exposure, and did not depend on a complex delivery platform.
The key regulatory issues were typical for ACE inhibitors:
- Contraindication during pregnancy
- Risk of angioedema
- Renal-function monitoring
- Potassium monitoring
- Dose adjustment in renal impairment
- Interaction concerns with diuretics and other blood-pressure medicines
The FDA label also identified the use of moexipril in patients with hypertension, with dosing adjusted according to response and tolerability. [1]
What is the Orange Book status of UNIVASC?
The Orange Book status of a legacy product can change over time as an NDA is withdrawn, discontinued, or removed from active marketing. Historical Orange Book listings may contain patent information that is no longer commercially operative.
UNIVASC’s current commercial status should not be equated with the continued existence of a historical NDA record. An NDA may remain visible in regulatory databases even when:
- The brand is no longer marketed.
- The product is listed as discontinued.
- No active branded sales remain.
- Generic equivalents have replaced the original product.
- Historical patent listings have expired.
No current commercial conclusion should be based only on the presence of an old FDA record.
Which companies challenged or replaced UNIVASC?
The relevant competitive threat came from generic manufacturers and from therapeutic substitutes within the ACE-inhibitor and broader antihypertensive markets.
Potential generic competitors included manufacturers with ANDA portfolios in cardiovascular products. The most important competitive mechanisms were:
- ANDA approval after expiry or loss of enforceable protection
- Paragraph IV certification against listed patents
- Abbreviated clinical requirements
- Pharmacy-level substitution
- Formulary preference for lower-cost ACE inhibitors
- Switching to lisinopril, enalapril, ramipril, or other established products
A public record of a major, commercially consequential Paragraph IV dispute involving UNIVASC is not established here. The absence of a documented high-profile case does not mean that no certification or patent dispute occurred. It means that the available record does not support identifying a specific challenger or settlement agreement with confidence.
What generic entry risks affected UNIVASC?
Generic entry risk was high because moexipril is a conventional small molecule administered in standard oral tablets. The product did not present the technical barriers associated with injectable biologics, inhaled devices, depot formulations, or complex controlled-release systems.
Generic launch scenarios
| Scenario |
Effect on UNIVASC |
| First generic approval |
Sharp reduction in brand price and market share |
| Multiple generic entrants |
Rapid commoditization |
| Limited generic supply |
Temporary price stability, but weak long-term protection |
| Brand discontinuation |
Generic substitution becomes the dominant channel |
| Therapeutic substitution |
Additional volume loss even where moexipril remains available |
The main commercial risk was not a single competitor. It was cumulative substitution by lower-cost ACE inhibitors and other antihypertensive classes.
How did UNIVASC compare with competing ACE inhibitors?
| Drug |
Competitive position versus UNIVASC |
| Lisinopril |
Stronger generic penetration and broad physician familiarity |
| Enalapril |
Long-established ACE inhibitor with extensive clinical use |
| Ramipril |
Strong cardiovascular-outcomes positioning in selected markets |
| Benazepril |
Established hypertension and combination-product presence |
| Quinapril |
Similar class competition, though also subject to later commercial decline |
| Captopril |
Older product with dosing and tolerability limitations |
| Moexipril |
Smaller commercial footprint and limited differentiation |
UNIVASC was positioned in a class where therapeutic interchangeability was relatively high. Physicians and payers could move patients among ACE inhibitors based on price, formulary status, dosing preference, renal considerations, and clinical familiarity.
This reduced the probability that moexipril could sustain premium pricing after generic competition emerged.
What was UNIVASC’s revenue trajectory?
Public company filings generally do not provide a separate revenue line for UNIVASC. The product was part of a broader prescription portfolio, and reported financial results were typically aggregated by business segment or geographic region.
The likely revenue trajectory was:
- Launch phase: Revenue grew as the product gained distribution and physician adoption.
- Maturity phase: Growth slowed because the ACE-inhibitor market was crowded.
- Pre-generic erosion: Reimbursement pressure and competing branded therapies reduced net price.
- Post-generic phase: Volume and price declined rapidly.
- Terminal phase: Brand revenue became immaterial or ceased after portfolio rationalization.
UNIVASC was unlikely to have generated the scale of sales associated with major primary-care cardiovascular brands. Its principal economic value was tied to the initial period of patent-protected sales rather than long-term franchise durability.
What licensing deals affected UNIVASC?
Schwarz Pharma was the original commercial sponsor associated with UNIVASC. Schwarz Pharma was acquired by UCB in 2006, creating a broader corporate portfolio and changing the ownership context for legacy products. [2]
The acquisition did not create a new growth thesis for UNIVASC. Legacy antihypertensive products were generally evaluated against portfolio priorities, manufacturing costs, regulatory obligations, and declining branded demand.
No major current licensing transaction appears to define UNIVASC’s commercial position. Any historical licensing or regional distribution agreements would need to be reviewed in original transaction documents because corporate annual reports generally do not provide complete product-level terms.
What litigation and settlement agreements affected UNIVASC?
No major active litigation involving UNIVASC is identified in the sources used for this assessment. The likely litigation exposure was concentrated in the period before or around generic entry, when patent holders could challenge ANDA certifications.
Potential case types included:
- Patent-infringement actions under the Hatch-Waxman Act
- Paragraph IV litigation
- ANDA litigation over compound or formulation claims
- Labeling disputes involving method-of-use claims
- Regulatory disputes over discontinued marketing status
No confirmed settlement agreement is identified here that materially delayed generic entry or created a current exclusivity barrier.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are low. Moexipril tablets are conventional oral solid dosage products, and production does not require a biologic facility, sterile fill-finish operation, specialized injector, or complex cold chain.
Residual barriers could include:
- Access to qualified active pharmaceutical ingredient suppliers
- Stability and impurity-control requirements
- Bioequivalence testing
- Regulatory maintenance costs
- Country-specific registration
- Historical process patents
- Supply-chain economics for a low-volume generic product
These barriers may affect the number of suppliers in small markets, but they are unlikely to support durable premium pricing.
Is UNIVASC still commercially relevant?
UNIVASC has low current commercial relevance in the United States and other mature pharmaceutical markets. Its strategic value is primarily historical.
The product may retain limited relevance in:
- Markets where moexipril remains registered
- Countries with fewer ACE-inhibitor alternatives
- Generic portfolios seeking incremental cardiovascular products
- Licensing transactions involving legacy regulatory approvals
- Historical patent or litigation research
It is not a credible late-stage growth asset without evidence of active sales, a protected geographic market, or a surviving patent with meaningful blocking power.
Key Takeaways
- UNIVASC is the former brand for moexipril hydrochloride, an ACE inhibitor for hypertension.
- The product entered a crowded cardiovascular market in the mid-1990s.
- Its commercial performance was constrained by limited differentiation and strong therapeutic substitution.
- Generic entry created high price and volume erosion risk.
- Public sources do not establish reliable product-level UNIVASC revenue.
- The product was associated with Schwarz Pharma, later acquired by UCB.
- Current branded value is low, and the product is best treated as a legacy asset.
- Formulation and manufacturing barriers are limited compared with biologics or complex drug-delivery products.
- No major current Paragraph IV dispute, settlement, or litigation matter is established in the reviewed record.
- The economic outlook is driven by residual generic demand rather than branded growth.
FAQs
Is UNIVASC the same as moexipril?
Yes. UNIVASC is the brand name for moexipril hydrochloride, an oral ACE inhibitor used to treat hypertension.
Is UNIVASC still available in the United States?
UNIVASC is not a meaningful active branded product in the U.S. market. Availability may differ by country and by generic manufacturer.
Did UNIVASC have a patent-protected market?
Yes. As a branded prescription product, UNIVASC was commercialized during a period of patent and regulatory protection. The precise historical patent-expiration date requires a complete Orange Book and patent-family review.
Are there biosimilars to UNIVASC?
No. UNIVASC is a small-molecule drug, not a biologic. Competition occurs through generic drug approval rather than the biosimilar pathway.
What drugs replaced UNIVASC?
Lisinopril, enalapril, ramipril, benazepril, quinapril, and other antihypertensive medicines provided therapeutic alternatives. Generic pricing and formulary status generally determined product selection.
References
-
U.S. Food and Drug Administration. (2001). Univasc (moexipril hydrochloride) tablets: Prescribing information. FDA.
-
UCB. (2006). Annual report 2006. UCB S.A.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
